Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?

Atilla E., Sahin U., Atilla P. A., Merter M., PEKER E., CEYHAN K., ...Daha Fazla

Hematology/ Oncology and Stem Cell Therapy, cilt.12, sa.4, ss.220-225, 2019 (Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 12 Sayı: 4
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.hemonc.2018.02.001
  • Dergi Adı: Hematology/ Oncology and Stem Cell Therapy
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.220-225
  • Anahtar Kelimeler: Allogeneic stem cell transplantation, Graft versus leukemia effect, Primary central nervous system lymphoma
  • Ankara Üniversitesi Adresli: Evet

Özet

© 2018 King Faisal Specialist Hospital & Research CentrePrimary central nervous system lymphoma (PCNSL), has an aggressive course and in untreated patients median survival is limited to three months. For relapsed PCNSL, the treatment options are few and results are usually unsatisfactory. Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) has been widely used for treatment of relapsed/refractory NHL patients. However there are limited data whether graft versus lymphoma effect can work in PCNSL patients. Here, we present a relapsed refractory PCNSL case treated by allo-HCT.